Is exenatide the next big thing in Parkinson's disease?

Is Exenatide a Treatment for Parkinson's Disease?

There is growing interest in the use of glucagon-like peptide-1 agonists as treatments for Parkinson's disease following the recent publication of the results of the Exenatide-PD trial. In this randomized, double-blind, placebo controlled trial, patients with moderate stage Parkinson's disease treated with once-weekly subcutaneous injections of exenatide 2 mg (Bydureon) for 48 weeks, had a 3.5-...

Motor and cognitive advantages persist 12 months after exenatide exposure in Parkinson's disease.

BACKGROUND Data from an open label randomised controlled trial have suggested possible advantages on both motor and non-motor measures in patients with Parkinson's disease following 12 months exposure to exenatide. OBJECTIVE Continued follow up of these same patients was performed to investigate whether these possible advantages persisted in the prolonged absence of this medication. METHODS...

THE BIG IDEA Beware the Next Big Thing

The Next Big Thing: Position Statements

This panel is a celebration of artiicial intelligence (AI). Basing its claims to interest on the past accomplishments of AI, it highlights some of the new exciting concepts and technologies that compete for the title The Next Big Thing.

Adapting to Learn, Learning to Adapt

The Next Big Thing Adaptive, or personalized, learning is becoming the next big thing in online education. By providing each student with a custom, personalized path through courses and tracking both content covered and level of attained mastery, adaptive learning platforms hold great promise for enhancing student learning and success. Adaptive course content is organized as a set of nodes in a...